TP53 Variants and Glioblastoma Prognosis
Author Information
Author(s): Esperante Diego, Galicia Kena Daza, Rivas-Cuervo Kalu Gabriel, Cacho-Díaz Bernardo, Trejo-Becerril Catalina, Taja-Chayeb Lucia, Aboud Orwa, Carlos-Escalante José Alberto, Wegman-Ostrosky Talia
Primary Institution: Universidad Nacional Autónoma de México (UNAM)
Hypothesis
This systematic review investigates the relationship between somatic TP53 oncogenic variants and prognosis in glioblastoma patients.
Conclusion
The presence of TP53 oncogenic variants is associated with a lower likelihood of 1-year survival in glioblastoma patients, but does not significantly impact overall survival or progression-free survival.
Supporting Evidence
- TP53 oncogenic variants were associated with a reduced likelihood of 1-year survival.
- The analysis did not reveal any significant impact of TP53 variants on overall survival or progression-free survival.
- 2,555 patients were included in the systematic review, with 716 having reported oncogenic variants.
Takeaway
This study looked at how certain gene changes in glioblastoma patients affect their chances of surviving. It found that while these changes might lower the chance of living for one year, they don't really help predict how long someone will live overall.
Methodology
This systematic review included longitudinal studies and clinical trials with at least 40 adult participants diagnosed with glioblastoma, assessing TP53 variant status.
Potential Biases
Most studies had at least one domain rated with a suboptimal risk of bias, particularly in the confounding domain.
Limitations
The study faced limitations such as underpowered analyses, high risk of bias in many included studies, and insufficient data on treatment responses.
Participant Demographics
The included studies primarily involved adults diagnosed with supratentorial glioblastoma, with a median age of around 60 years.
Statistical Information
P-Value
0.03
Confidence Interval
0.29–0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website